Expanded US patent for Arthritis joint injection

5/24/2018: Just learned that on June 5, 2018, U.S. Patent No. 9,987,296 will be published.

It is a continuation of a prior more general patent for intra articular injection to treat arthritis. This patent expanded the use of the common plant dye, Cyanidin-3-glucoside to include dextrose and addition of insulin or other growth hormones as well as slow release biodegradable vehicle.

Allowed Claims
1. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject by an intra-articular injection, a composition comprising cyanidin-3-glucoside (C3G), glucose and a pharmaceutically acceptable carrier, wherein the concentration of glucose is about 5%, and wherein the C3G is administered at a dose of 0.002 mg to 100 mg per joint that is effective to elicit the inhibition of IL-1 induced GAG release in the arthritic joint of the subject.

2-3. (Cancelled)

4. The method according to claim 1, wherein the composition increases expression of IGF-1 in the arthritic joint.

5. The method according to claim 4, wherein the composition is provided in a biodegradable microsphere.

6. The method according to claim 5, wherein the biodegradable microsphere comprises a slow release bioabsorbable material.

7. The method according to claim 6, wherein the bioadsorbable material is 50/50 D, L lactide/glycolide or 85/15 D, L lactide/glycolide.

8. (Cancelled)

9. The method according to claim 1, wherein the composition has a chondroprotective and/or chondronutritive effect in the joint of a subject.

10. (Cancelled)

11. The method of claim 1, wherein the composition treats damaged cartilage in the arthritic joint.

12-15. (Cancelled)

16. The method of claim 1, wherein the joint is a synovial joint.

17. The method of claim 11, wherein the injection comprises the formation of anthocyanin metabolites in the synovial fluid.

18. The method according to claim 1, wherein the dose of 0.002 mg to 100 mg per joint of C3G is provided at a concentration not exceeding about 100 ┬ÁM.

19. The method according to claim 1, wherein the composition is administered with IGF-1, insulin, or a mixture thereof.

20. A method for treating damaged cartilage in an arthritic joint in a subject, comprising administering into the arthritic joint of the subject, by an intra-articular injection, a composition that is a solution comprising an anthocyanin, glucose and a pharmaceutically acceptable carrier, wherein the concentration of the glucose is about 0.5% to about 10%;
wherein the anthocyanin is cyanidin-3-glucoside (C3G), and wherein the C3G is administered at a dose of 0.002 mg to 100 mg per joint.

21. The method according to claim 20, wherein the composition increases production of insulin-like growth factor-1 (IGF-1) in the joint.

22. The method according to claim 20, wherein the glucose is administered at about 5%.

23. The method according to claim 20, wherein the glucose is administered at about 10%.

Comments

comments